Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Sathornsumetee, Sith, Rich, Jeremy N., Quinn, Jennifer A., Lagattuta, Theodore F., Egorin, Merrill J., Gururangan, Sridharan, McLendon, Roger, Herndon, James E., Friedman, Allan H., Salvado, August J., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: Duke University Press 2008
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2563055/
https://ncbi.nlm.nih.gov/pubmed/18359865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados